Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Vidadi Yusibov"'
Autor:
Bhupal Ban, Rodell C. Barrientos, Therese Oertel, Essie Komla, Connor Whalen, Megan Sopko, Yingjian You, Partha Banerjee, Agnieszka Sulima, Arthur E. Jacobson, Kenner C. Rice, Gary R. Matyas, Vidadi Yusibov
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
The prevalence and societal impact of opioid use disorder (OUD) is an acknowledged public health crisis that is further aggravated by the current pandemic. One of the devastating consequences of OUD is opioid overdose deaths. While multiple medicatio
Externí odkaz:
https://doaj.org/article/a57dc3421a724889a100c3b2663a617c
Autor:
Stephen, Tottey, Yoko, Shoji, R, Mark Jones, Konstantin, Musiychuk, Jessica A, Chichester, Kazutoyo, Miura, Luwen, Zhou, Shwu-Maan, Lee, Jordan, Plieskatt, Yimin, Wu, Carole A, Long, Stephen J, Streatfield, Vidadi, Yusibov
Publikováno v:
Vaccine. 41:938-944
Malaria kills around 409,000 people a year, mostly children under the age of five. Malaria transmission-blocking vaccines work to reduce malaria prevalence in a community and have the potential to be part of a multifaceted approach required to elimin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63f2662ee03d49f5181c45c43212fb35
https://doi.org/10.1016/j.vaccine.2022.12.048
https://doi.org/10.1016/j.vaccine.2022.12.048
Autor:
Crystal W Burke, Jeffery W Froude, Franco Rossi, Charles E White, Crystal L Moyer, Jane Ennis, M Louise Pitt, Stephen Streatfield, R Mark Jones, Konstantin Musiychuk, Jukka Kervinen, Larry Zeitlin, Vidadi Yusibov, Pamela J Glass
Publikováno v:
PLoS Pathogens, Vol 15, Iss 12, p e1008157 (2019)
There are no FDA licensed vaccines or therapeutics for Venezuelan equine encephalitis virus (VEEV) which causes a debilitating acute febrile illness in humans that can progress to encephalitis. Previous studies demonstrated that murine and macaque mo
Externí odkaz:
https://doaj.org/article/b68e416819474dbc8869926f3c9561c6
Autor:
Stephen W. Scally, Brandon McLeod, Alexandre Bosch, Kazutoyo Miura, Qi Liang, Sean Carroll, Sini Reponen, Ngan Nguyen, Eldar Giladi, Sebastian Rämisch, Vidadi Yusibov, Allan Bradley, Franck Lemiale, William R. Schief, Daniel Emerling, Paul Kellam, C. Richter King, Jean-Philippe Julien
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
Plasmodium falciparum protein Pfs25 is a promising malaria transmission blocking vaccine antigen. Here, Scally et al. determine the crystal structure of Pfs25 and identify antigenic sites that are recognized by transmission-blocking antibodies elicit
Externí odkaz:
https://doaj.org/article/d1902f6099734fd8a2c75117c776ee4d
Autor:
Vanessa Neuhaus, Dirk Schaudien, Tatiana Golovina, Ulla-Angela Temann, Carolann Thompson, Torsten Lippmann, Claus Bersch, Olaf Pfennig, Danny Jonigk, Peter Braubach, Hans-Gerd Fieguth, Gregor Warnecke, Vidadi Yusibov, Katherina Sewald, Armin Braun
Publikováno v:
Journal of Occupational Medicine and Toxicology, Vol 12, Iss 1, Pp 1-8 (2017)
Abstract Background Investigation of basic chronic inflammatory mechanisms and development of new therapeutics targeting the respiratory tract requires appropriate testing systems, including those to monitor long- persistence. Human precision-cut lun
Externí odkaz:
https://doaj.org/article/377b9b8e39534e4e942d22fbfdcf97fa
Autor:
Teen-Lee Pua, Xiao Ying Chan, Hwei-San Loh, Abdul Rahman Omar, Vidadi Yusibov, Konstantin Musiychuk, Alexandra C. Hall, Megan V. Coffin, Yoko Shoji, Jessica A. Chichester, Hong Bi, Stephen J. Streatfield
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 2, Pp 306-313 (2017)
Highly pathogenic avian influenza (HPAI) H5N1 is an ongoing global health concern due to its severe sporadic outbreaks in Asia, Africa and Europe, which poses a potential pandemic threat. The development of safe and cost-effective vaccine candidates
Externí odkaz:
https://doaj.org/article/0392af64b6c54e2eb1404e47bdafbb95
Autor:
Angela Temann, Tatiana Golovina, Vanessa Neuhaus, Carolann Thompson, Jessica A. Chichester, Armin Braun, Vidadi Yusibov
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 2, Pp 351-358 (2017)
The development of systems that are more accurate and time-efficient in predicting safety and efficacy of target products in humans are critically important in reducing the cost and duration of pharmaceutical development. To circumvent some of the li
Externí odkaz:
https://doaj.org/article/bc25d27b58ff4ad1bde5bda29987b85e
Autor:
Kristopher M, Paolino, Jason A, Regules, James E, Moon, Richard C, Ruck, Jason W, Bennett, Shon A, Remich, Kristin T, Mills, Leyi, Lin, Cadeidre N, Washington, Ghariwayne A, Fornillos, Changhong Y, Lindsey, Kristan A, O'Brien, Meng, Shi, R, Mark Jones, Brian J, Green, Stephen, Tottey, Jessica A, Chichester, Stephen J, Streatfield, Vidadi, Yusibov
Publikováno v:
Vaccine. 40:1864-1871
The potential use of Bacillus anthracis as a bioterrorism weapon requires a safe and effective vaccine that can be immediately distributed for mass vaccination. Protective antigen (PA), a principal component of virulence factors edema toxin and letha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbe3a4cfd8259275aee5d7324600c5a2
https://doi.org/10.1016/j.vaccine.2022.01.047
https://doi.org/10.1016/j.vaccine.2022.01.047
Autor:
Vidadi Yusibov, Shailaja Rabindran, Marina Skarjinskaia, Elisabeth Knapp, Masaaki Fujiki, Oleg Fedorkin, Gourgopal Roy
Publikováno v:
Viruses, Vol 5, Iss 7, Pp 1802-1814 (2013)
Alfalfa mosaic virus (AlMV) RNAs 1 and 2 with deletions in their 3' non‑translated regions (NTRs) have been previously shown to be encapsidated into virions by coat protein (CP) expressed from RNA3, indicating that the 3' NTRs of RNAs 1 and 2 are n
Externí odkaz:
https://doaj.org/article/e3a9d922957c4c54a58940e263f143cf
Autor:
Tarlan Mamedov, Jessica A Chichester, R Mark Jones, Ananya Ghosh, Megan V Coffin, Kristina Herschbach, Alexey I Prokhnevsky, Stephen J Streatfield, Vidadi Yusibov
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0153956 (2016)
Bacillus anthracis has long been considered a potential biological warfare agent, and therefore, there is a need for a safe, low-cost and highly efficient anthrax vaccine with demonstrated long-term stability for mass vaccination in case of an emerge
Externí odkaz:
https://doaj.org/article/8af4f0aaf9a54510b00a25fb645e57f5